Alnylam Pharmaceuticals (ALNY) Achieved Free Cash Flow Breakeven in 2025

2 months ago 24

Soumya Eswaran

Thu, April 9, 2026 astatine 9:22 AM CDT 3 min read

ClearBridge Investments, a planetary equity manager, precocious published first-quarter 2026 commentary for its “Large Cap Growth Strategy”. A transcript of the missive tin beryllium downloaded here. Following the outbreak of the Middle East conflict, the marketplace experienced a important diminution successful maturation stocks, resulting successful important losses. In the quarter, the S&P 500 Index fell 4.3% portion the benchmark Russell 1000 Growth Index declined 9.8%, compared to the Russell 1000 Value Index’s 2.1% gain. In a volatile environment, the ClearBridge Large Cap Growth Strategy outperformed its benchmark, benefiting from a displacement distant from exertion and momentum stocks that led the marketplace successful 2025. The strategy saw a affirmative reversal successful connection services and beardown enactment from cyclical maturation sectors similar industrials, materials, and parts of IT. The Strategy repositioned its portfolio to summation vulnerability successful semiconductors and biopharmaceuticals, and exited positions with turnaround delays to support discipline. In addition, delight cheque the Strategy’s apical 5 holdings to cognize its champion picks successful 2026.

In its first-quarter 2026 capitalist letter, ClearBridge Large Cap Growth Strategy highlighted stocks specified arsenic Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is simply a biopharmaceutical institution that discovers and commercializes therapeutics based connected ribonucleic acerb interference. The one-month instrumentality of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) was 3.16%, and its shares gained 44.62% of their worth implicit the past 52 weeks. On April 8, 2026, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) banal closed astatine $327.25 per share, with a marketplace capitalization of $43.66 billion.

ClearBridge Large Cap Growth Strategy stated the pursuing regarding Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) successful its Q1 2026 capitalist letter:

"We besides added 2 caller positions successful the wellness attraction assemblage with the additions of Roche and Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Alnylam has pioneered RNAi drugs that enactment to "silence" definite proteins created by the assemblage that tin malfunction and origin disease. The company’s cardinal product, Amvuttra, treats a information that leads to macromolecule misfolding successful the bosom and, eventually, bosom nonaccomplishment (cardiomyopathy). While Amvuttra entered the cardiomyopathy marketplace to beardown aboriginal occurrence successful 2025, missed expectations heading into 2026 provided a accidental to bargain the banal astatine valuation levels we deliberation incorporated blimpish assumptions for its commercialized accidental and precise small worth for immoderate different pipeline drugs. Alnylam besides reached escaped currency travel breakeven successful 2025, a milestone that we question successful biotech investments to derisk immoderate downside potential."

Read Entire Article